AlphaYouJZ
Insider selling
Jonathan Zalevsky sold $13K of Nektar Therapeutics (NKTR) stock
Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), sold 186 shares of NKTR stock worth $13K, per an SEC Form 4 filed Aug 20, 2026.
It was an open-market sale.
The trade happened on Aug 18, 2026, 2 days before it was made public.
NKTR has moved -9.2% since the trade date, from $73.64 to $66.84 (Sep 21, 2026 close).
- Traded
- Aug 18, 2026
- Disclosed
- Aug 20, 2026
- Filing delay
- 2 days
- Price since
- -9.2%
- Role
- Chief R&D Officer
- Source
- SEC Form 4
More NKTR insider and Congress trades
From a public SEC Form 4, linked above. Not investment advice, and not a recommendation to buy or sell.